Venn Life Sciences Holdings PLC (LON:VENN) has been retained to Speculative Buy in a statement by Beaufort Securities earlier today.
- Updated: October 9, 2016
Boasting a price of 0.00GBX, Venn Life Sciences Holdings PLC (LON:VENN) traded -1.05% lower on the day. With the last close down -12.58% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Venn Life Sciences Holdings PLC has recorded a 50-day average of 27.51GBX and a two hundred day average of 26.31GBX. Volume of trade was down over the average, with 49,358 shares of VENN changing hands under the typical 77,080
Beaufort Securities has retained Venn Life Sciences Holdings PLC (LON:VENN) to Speculative Buy in a statement released on 10/5/2016. They are also stating a potential upside of 0%.
With a total market value of 0 GBX, Venn Life Sciences Holdings PLC has with a one year low of 17.55GBX and a one year high of 30.30GBX .
More About Venn Life Sciences Holdings PLC (LON:VENN)
Venn Life Sciences Holdings plc is a clinical research organization (CRO), which is engaged in providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology and medical device organizations. The Company has the innovation segment, which is focused on developing and commercializing skin technologies. It provides drug development services through its subsidiary, Kinesis Pharma B.V. The Company's drug development services include clinical development, pharmaceutical development, non-clinical/pre-clinical development, drug candidate selection and drug development project management. The Company offers international clinical research services, including protocol development; feasibility and site selection; investigator and site selection; project management; site management and monitoring; vendor management, and quality assurance. The Company has its presence in the United Kingdom, Ireland, France, Netherlands, Germany and Singapore.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.